Valneva SE announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished RD leader to oversee the further evolution of the Company's RD portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva's pre-clinical and translational RD activities in support of the Company's strategic ambition to provide first-, best- or only-in-class vaccine solutions.

Dr. Schuitemaker brings more than two decades of experience in vaccine discovery and development. She formerly served as Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson Johnson (JJ), with responsibility for the strategy and execution of vaccine programs on COVID-19, HIV, RSV, Ebola, and multiple other viral disease targets for almost 14 years. Prior to JJ, she worked at Sanquin, The Netherlands' Blood Supply Foundation, and at Amsterdam University Medical Center, where she conducted research on the pathogenesis of HIV.

She has a unique and solid scientific background, which is notably reflected in more than 350 scientific.